GlassScriptPhysician profile
Ayman S Al-Hakim
NPI 1447313085
$3,190.55
in general payments reported to CMS, 2019-2025
35 companies · $1,122 in 2025
The $1,122 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2021: $99.00 · 2023: $541 · 2024: $1,215 · 2025: $1,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,878.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $496.48 | 2023-2025 | Tagrisso, Imfinzi, Calquence |
| Pfizer INC. | $298.42 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $281.50 | 2024-2025 | |
| Abbvie INC. | $235.54 | 2024-2025 | |
| Daiichi Sankyo INC. | $201.06 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Myriad Genetic Laboratories, INC. | $180.60 | 2023 | Myrisk |
| Karyopharm Therapeutics INC. | $175.96 | 2024-2025 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $124.00 | 2019-2025 | Alunbrig, Ninlaro, Hyqvia |
| Incyte Corporation | $115.72 | 2021-2025 | Jakafi |
| Merck Sharp & Dohme LLC | $115.72 | 2019-2024 | Keytruda, Welireg, Lynparza |
| Lilly USA, LLC | $92.31 | 2024-2025 | Verzenio, Jaypirca |
| Janssen Biotech, INC. | $92.17 | 2023-2025 | Darzalex, Rybrevant, Imbruvica |
| Celgene Corporation | $78.74 | 2023-2024 | Reblozyl, Pomalyst |
| Genentech USA, INC. | $52.73 | 2024 | Polivy, Columvi, Lunsumio |
| Pharmacosmos Therapeutics INC. | $51.64 | 2025 | Monoferric |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $48.57 | 2024-2025 | Libtayo |
| Foundation Medicine, INC. | $46.84 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.32 | 2024 | |
| Gilead Sciences, INC. | $43.74 | 2024 | |
| Exelixis INC. | $41.28 | 2019 | |
| Jazz Pharmaceuticals INC. | $39.16 | 2025 | |
| Sumitomo Pharma America, INC. | $38.94 | 2025 | Orgovyx |
| Genzyme Corporation | $32.25 | 2025 | |
| Argenx US, INC. | $30.03 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Beigene USA, INC. | $28.52 | 2024 | Brukinsa |
| Tempus Ai, INC | $27.32 | 2025 | Xt Cdx |
| Mirati Therapeutics, INC. | $25.23 | 2023 | Krazati |
| Eisai INC. | $24.29 | 2024 | |
| Beone Medicines USA, INC. | $21.48 | 2025 | Brukinsa |
| Coherus Oncology, INC. | $20.61 | 2024 | |
| Array Biopharma INC | $17.94 | 2024 | Mektovi, Tukysa, Braftovi |
| Alexion Pharmaceuticals, INC. | $17.83 | 2024 | Ultomiris |
| Immunogen, INC. | $17.44 | 2023 | Elahere |
| Amgen INC. | $15.63 | 2024 | Prolia, Evenity |
| Kyowa Kirin, INC. | $15.54 | 2024 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayman Al-Hakim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.